PetVivo Holdings Posts $7.5M Net Loss as Revenue Slips 2% in Nine Months Through December
PetVivo Holdings reported a net loss of $7.5 million for the nine months ending December 31, 2025, widening from a $6.0 million loss in the year-earlier period. Revenue edged down 2% to $886,892 as the veterinary medical device company burned through $5.3 million in cash from operations.
Revenue Dips as Losses Mount
PetVivo Holdings reported revenue of $886,892 for the nine months ending December 31, 2025, down 2% from $907,783 in the same period a year earlier. The Nevada-based veterinary medical device company posted a net loss of $7.5 million, compared to a $6.0 million loss in the prior-year period. Read more earnings reports.
For the three months ending December 31, 2025, revenue fell 51% to $286,108 from $583,313 a year earlier. The quarterly net loss widened to $2.2 million from $1.8 million.
Operating Expenses Hold Steady
Operating expenses for the nine-month period totaled $6.7 million, down slightly from $6.8 million a year earlier. Research and development spending declined to $924,937 from $1.2 million in the prior-year period. Gross profit for the nine months fell to $551,496 from $812,130, reflecting higher cost of goods sold that jumped to $335,396 from $95,653.
Cash Burn Accelerates
Cash used in operations totaled $5.3 million for the nine months, compared to $4.1 million in the year-earlier period. The company raised $5.1 million through financing activities during the same period, down from $4.1 million a year earlier.
Balance Sheet Shrinks
Total assets dropped to $4.4 million as of December 31, 2025, from $9.3 million at the end of fiscal 2025 on March 31. Current assets fell to $1.4 million from $5.6 million over the same period. Total liabilities decreased to $997,404 from $5.1 million, while stockholders' equity slipped to $3.4 million from $4.2 million.
Accounts payable fell to $385,641 from $821,081. Inventory rose to $605,390 from $323,504 as of March 31, 2025.
Share Count Increases
Common shares outstanding increased to 34.5 million at December 31, 2025, from 24.2 million at the end of fiscal 2025. The company reported a loss per share of $0.27 for the nine-month period, compared to $0.30 in the prior year. For the most recent quarter, loss per share was $0.07 versus $0.09 a year earlier.
| Metric | 9 Months Ending Dec 31, 2025 | 9 Months Ending Dec 31, 2024 |
|---|---|---|
| Revenue | $886,892 | $907,783 |
| Net Loss | ($7,510,301) | ($5,979,594) |
| Operating Expenses | $6,652,635 | $6,788,008 |
| Cash from Operations | ($5,294,904) | ($4,091,978) |
| Loss Per Share | ($0.27) | ($0.30) |
| Balance Sheet | December 31, 2025 | March 31, 2025 |
|---|---|---|
| Total Assets | $4,376,154 | $9,339,195 |
| Current Assets | $1,383,278 | $5,609,567 |
| Total Liabilities | $997,404 | $5,119,947 |
| Stockholders' Equity | $3,378,750 | $4,219,248 |
| Shares Outstanding | 34,450,942 | 24,181,537 |